An updated December 2025 ERS clinical practice guideline provides evidence-based recommendations for managing adult ...

Brensocatib, the first FDA-approved medication to treat non-cystic fibrosis bronchiectasis, can reduce symptoms of the ...

The MHRA has licensed brensocatib as the first disease-specific therapy for non-cystic fibrosis bronchiectasis in patients with recurrent exacerbations.

The Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for brensocatib (Brinsupri), a new medicine for people aged 12 and over with non‑cystic fibrosis ...

The Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for brensocatib, branded as Brinsupri, marking the first time a medicine specifically designed to treat ...

Bronchiectasis is a complex and heterogeneous disease, and our current understanding of its pathophysiological mechanisms remains in its infancy. Currently, few specifically approved treatments for ...

Archana Koirala has done research with funding from the Australian Department of Health, Disability and Ageing, and NSW health. She is the chair of the Vaccination Special Interest Group and a ...

Anyone who has dealt with a lingering cough knows how quickly it can take over daily life. It interrupts conversations, disrupts sleep and makes even simple things like eating or drinking ...

Dr. Linda M. Morris (Medicine): An 80-year-old woman was admitted to this hospital because of cough and hypoxemia. The patient had been in her usual state of health — active in her community and ...